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Muscarinic and purinergic (P2X) receptors play critical roles in bladder urothelium under physiological
and pathological conditions. Aim of present study was to characterize these receptors in rat bladder
urothelium and detrusor muscle using selective radioligands of [N-methyl-3H]scopolamine methyl
chloride ([3H]NMS) and ab-methylene ATP [2,8-3H]tetrasodium salt ([3H]ab-MeATP). Similar binding
parameters for each radioligand were observed in urothelium and detrusor muscle. Pretreatment with N-
(2-chloroethyl)-4-piperidinyl diphenylacetate (4-DAMP mustard) mustard revealed co-existence of M2
and M3 receptors, with the number of M2 receptors being larger in the urothelium and detrusor muscle.
Intravesical administration of imidafenacin and Dpr-P-4 (N / O) (active metabolite of propiverine)
displayed signiﬁcant binding of muscarinic receptors in the urothelium and detrusor muscle. The
treatment with cyclophosphamide (CYP) or resiniferatoxin (RTX) resulted in a signiﬁcant decrease in
maximal number of binding sites (Bmax) for [3H]NMS and/or [3H]ab-MeATP in the urothelium and
detrusor muscle. These results demonstrated that 1) pharmacological characteristics of muscarinic and
P2X receptors in rat bladder urotheliumwere similar to those in the detrusor muscle, 2) that densities of
these receptors were signiﬁcantly altered by pretreatments with CYP and RTX, and 3) that these re-
ceptors may be pharmacologically affected by imidafenacin and Dpr-P-4 (N/ O) which are excreted in
the urine.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Overactive bladder (OAB) is a chronic syndrome that is charac-
terized by increases in frequency of micturition, urgency, and urge
incontinence, having negative impacts on health-related quality of
life (QoL) (1,2). Antimuscarinic agents are the ﬁrst-line treatment
for OAB, and their effectiveness has been documented in clinicalne methyl chloride; [3H]ab-
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d/4.0/).trials (2). Physiological functions of acetylcholine in the bladder are
dependent on the site of muscarinic receptors, such as detrusor
muscle, pre-junctional terminals and sensory nerves, and urothe-
lium, in which they induce bladder contractions, modulate release
of chemical mediators, and inﬂuence afferent nerve activity,
respectively (3). Antimuscarinics have been suggested to exert
inhibitory effect on afferent nerve activity (2,4,5).
Bladder urothelium is a multifunctional tissue that acts not only
as barrier between vesical contents of lower urinary tract and un-
derlying tissues, but also as sensory organ by transducing physical
and chemical stresses to the attendant afferent nervous system and
underlying smooth muscle. Muscarinic receptor subtype was
detected in the human bladder urothelium (6). The urotheliumwas
shown to respond to stretch and muscarinic agonist stimuli by
releasing adenosine triphosphate (ATP), nitric oxide, and acetyl-
choline itself, which may, in turn, modulate afferent activity
through nerves and/or myoﬁbroblasts (7,8). Therefore, urothelialnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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agents. Previous studies reported that imidafenacin and an active
metabolite of propiverine were excreted in human urine at sufﬁ-
cient concentrations to exert pharmacological effects on bladder
(9,10).
Purinergic (P2X) receptors are considered to play a role in lower
urinary tract function, regulating both afferent and efferent
signaling pathways to control urine storage and elimination (11).
Subtypes of P2X2 and P2X3 in the urothelium are involved in sen-
sory functions, whereas P2X1 receptor is expressed predominantly
in detrusor muscle and play a role in efferent control of bladder
function (12). When bladder is stretched during the ﬁlling phase, it
releases ATP, whichmay act on receptors present on sensory nerves
in the urothelium, thereby conveying information to central ner-
vous system and initiating voiding (13). Therefore, urothelial P2X
receptors are also important for micturition.
Interstitial cystitis (IC) is a chronic inﬂammatory disease of
bladder characterized by urinary frequency, urgency, and supra-
pubic pain and relieved by voiding. Evidence to suggest that
abnormalities in muscarinic and purinergic signaling trans-
duction in the bladder are involved in the development of IC is
increasing (11,14e16). Bladder biopsy specimens from patients
with bladder obstruction or detrusor instability revealed that
distribution of purinergic receptors was altered under patholog-
ical conditions (17). RTX, an extremely potent vanilloid, having
desensitizing effects at nanomolar concentrations (18), was pre-
viously shown to effectively improve urinary frequency, urgency,
and urge incontinence in patients (19). Antimuscarinic agents
have been suggested to decrease bladder afferent activity by
blocking urothelial muscarinic receptors, thereby improving OAB
symptoms (20). However, muscarinic and purinergic receptors in
the urothelium have not been directly identiﬁed. The present
study aimed to characterize these receptors simultaneously in the
urothelium and detrusor muscle of rat bladders, using selective
radioligands.
2. Methods
2.1. Materials
[N-methyl-3H]scopolamine methyl chloride ([3H]NMS, 3.03
TBq/mmol) and ab-methylene ATP [2,8-3H]tetrasodium salt ([3H]
ab-MeATP, 567 GBq/mmol) were purchased from PerkinElmer Life
Sciences, Inc. (Boston, MA). Imidafenacin was donated by Kyorin
Pharmaceutical Co., Ltd. (Tokyo, Japan). Propiverine hydrochloride
(propiverine), 1-methyl-4-piperidyl benzilate N-oxide (DPr-P-4
(N / O)), and PPADS (pyridoxal-phosphate-6-azophenyl-20, 40-
disulphonic acid tetrasodium) were donated by Taiho Pharmaceu-
tical Co., Ltd. (Saitama, Japan). 5-((3-phenoxybenzyl)[(1S)-1,2,3,4-
tetrahydro-1-naphthalenyl]aminocarbonyl)-1,2,4-
benzenetricarboxylic acid (A-317491) was purchased from Sigma-
Aldrich (St. Louis, MO, USA). 4-DAMP mustard was donated by Dr.
Frederick J. Ehlert. All other chemicals were obtained from com-
mercial sources.
2.2. Animals
Male Sprague-Dawley rats (250e300 g) at 8e10 weeks of age
were purchased from Japan SLC (Shizuoka, Japan). They were
housed in the laboratory with free access to food and water and
maintained on a 12-h light-dark cycle in a room with controlled
temperature (24 ± 24 C). Animal care and experiments were
performed in accordance with the guidelines for the care and use of
laboratory animals of the University of Shizuoka (registration
number: 136023).2.3. Drug administration
In experiments in which 4-DAMP mustard was used (21), the
tissue homogenate was incubated with 1 mM AF-DX116 at 37 C for
10 min to reversibly block M2 receptors, followed by the addition of
10 nM cyclized 4-DAMP mustard, and the homogenate was incu-
bated at 37 C for 60 min to irreversibly block M3 receptors and
centrifuged at 40,000 g for 10min. The resulting pellet was ﬁnally
resuspended in KRB buffer for the binding study.
In experiments in which chemical cystitis was induced by CYP,
rats received a single injection of CYP (150 mg/kg, i.p.) and survived
for 3 days after the injection (22). In order to intravesically instill
RTX, fasted rats were anesthetized with pentobarbital sodium
(50 mg/kg, i.p.) and their bladders were exposed. A 27-gauge
needle connected to a syringe was inserted into the bladder
through the bladder dome, and RTX was directly instilled in to the
bladder for 30 min. In order to intravesically instill imidafenacin
and DPr-P-4 (N/ O), these agents were directly instilled in to the
bladder for 30 min.2.4. Tissue preparation and binding assay for muscarinic and P2X
receptors
Rats were sacriﬁced by taking blood from the descending aorta
under anesthesia with pentobarbital sodium (50 mg/kg, i.p.). The
urothelium and detrusor muscle in the bladder were dissected,
minced with scissors, and the tissue homogenates were prepared
(22). Protein concentrations were measured using the BCA Protein
Assay Kit (Thermo scientiﬁc, Rockford, IL).
The binding assay for muscarinic and P2X receptors was per-
formed using [3H]NMS and [3H]ab-MeATP (22), respectively. In the
[3H]NMS binding assay, the homogenates of rat tissues were
incubated with different concentrations (0.06e1.5 nM) of [3H]NMS
in 30 mMNaþ/HEPES buffer (pH 7.5) for 60 min at 25 C. In the [3H]
ab-Me-ATP binding assay, the homogenates of rat tissues were
incubatedwith different concentrations (0.3e10 nM) of [3H]ab-Me-
ATP in 50 mM TriseHCl buffer (pH 7.4) for 60 min at 4 C. In the
competition experiment using muscarinic and P2X antagonists,
tissue homogenates were incubated with [3H]NMS (0.5 nM) and
[3H]ab-Me-ATP (3 nM). The reaction was terminated by rapid
ﬁltration (Cell Harvester; Brandel Co., Gaithersburg, MD) through
Whatman GF/B glass ﬁber ﬁlters, and the ﬁlters were then rinsed
three times with 3 mL of ice-cold buffer. Tissue-bound radioactivity
was extracted from the ﬁlters overnight by immersion in scintil-
lation ﬂuid, and radioactivity was determined by a liquid scintil-
lation counter. Speciﬁc binding of both radioligands was
determined experimentally from differences between counts in the
absence and presence of 1 mM atropine and 3 mM ab-MeATP,
respectively.2.5. Data analysis
[3H]NMS binding data were subjected to a non-linear regression
analysis using Graph Pad PRISM (ver. 5, Graph Pad Software, San
Diego, CA). The apparent dissociation constant (Kd) and maximal
number of binding sites (Bmax) were estimated for [3H]NMS and
[3H]ab-Me-ATP. The ability of antagonists to inhibit the speciﬁc
binding of [3H]NMS and [3H]ab-Me-ATP was estimated from the
IC50, which is the molar concentration of each agent needed to
displace 50% of speciﬁc binding. The inhibition constant, Ki, was
calculated from the equation, Ki ¼ IC50/(1 þ L/Kd), where L repre-
sents the concentration of [3H]NMS or [3H]ab-Me-ATP.
Statistical analyses were performed with the Student's t-test
and a one-way analysis of variance (ANOVA), followed by Dunnett's
Table 1
Ki values and Hill coefﬁcients (nH) for in vitro inhibition by imidafenacin, darife-
nacin, propiverine, and DPr-P-4 (N / O) of speciﬁc [3H]NMS binding in the uro-
thelium and detrusor muscle in the rat bladder.
Drug Urothelium Detrusor muscle
Ki (nM) nH Ki (nM) nH
Imidafenacin 3.91 ± 0.84 1.10 ± 0.11 3.66 ± 0.46 1.04 ± 0.07
Darifenacin 17.4 ± 2.4 0.76 ± 0.09 18.0 ± 5.9 0.73 ± 0.06
Propiverine 328 ± 33 0.92 ± 0.05 348 ± 21 1.09 ± 0.17
DPr-P-4 (N/ O) 186 ± 11 0.93 ± 0.07 231 ± 21 0.91 ± 0.04
The speciﬁc binding of [3H]NMS (0.5 nM) in rat tissues was measured in the absence
and presence of different concentrations of imidafenacin, darifenacin, propiverine,
and DPr-P-4 (N/ O). Ki and Hill coefﬁcients were estimated. Each value represents
the mean ± SEM of three to eight rats.
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mean ± S.E. Signiﬁcance was accepted at P < 0.05.
3. Results
3.1. Identiﬁcation of muscarinic and P2X receptors in urothelium
and detrusor muscle
The speciﬁc binding of [3H]NMS and [3H]ab-MeATP in homog-
enates of the urothelium and detrusor muscle increased in a
concentration-dependent manner and appeared to be saturated at
approximately 0.5 ([3H]NMS) and 3.0 ([3H]ab-MeATP) nM. The
calculated values of Kd and Bmax for speciﬁc [3H]NMS binding in the
urothelium (259 ± 24 pM and 105 ± 7 fmol/mg protein, respec-
tively) were similar to those in the detrusor muscle (289 ± 21 pM
and 125 ± 13 fmol/mg protein, respectively). No signiﬁcant differ-
ences were observed in the calculated Kd or Bmax values for speciﬁc
[3H]ab-MeATP binding between the urothelium (1219 ± 207 pM
and 9.00 ± 0.62 fmol/mg protein, respectively) and detrusor muscle
(1311 ± 97 pM and 11.1 ± 0.9 fmol/mg protein, respectively).
3.2. Inhibition of speciﬁc binding of [3H]NMS and [3H]ab-MeATP by
antimuscarinic agents and P2X receptor antagonists
Antimuscarinic agents such competedwith [3H]NMS for binding
sites in homogenates of the urothelium and detrusor muscle in a
concentration-dependent manner (Fig.1). Based on their Ki values,
the rank order of binding afﬁnities of these antimuscarinic agents
in the urothelium was imidafenacin > darifenacin > Dpr-P-4
(N / O) > propiverine (Table 1). No signiﬁcant difference was
observed in pKi values for antimuscarinic agents between theFig. 1. In vitro inhibition by muscarinic (upper panel) and purinergic (lower panel) agents o
muscle in the rat bladder. Upper panel, muscarinic agents: imidafenacin (-), darifenacin (
MeATP (C), A317491 (:), and PPADS (-). The ordinate is the speciﬁc binding of [3H]NMS (
concentrations of imidafenacin (1e300 nM), darifenacin (1e300 nM), DPr-P-4 (N/ O) (0.01
(1e100 nM), A317491 (1e100 mM) and PPADS (1e100 mM) (lower panel). Each point represurothelium and detrusor muscle. The Hill coefﬁcients were close to
unity for antimuscarinic agents, except for darifenacin.
ab-MeATP, A317491, and PPADS inhibited speciﬁc [3H]ab-MeATP
binding in homogenates of the urothelium and detrusor muscle in a
concentration-dependent manner (Fig. 1). The Ki values of each
agent in the urothelium were similar to those in the detrusor
muscle (Table 2). Based on their Ki values, the rank order of binding
afﬁnities of these P2X receptor antagonists in the bladder was ab-
MeATP > A317491 z PPADS. The Hill coefﬁcients for ab-MeATP,
A317491, and PPADS in these tissues were close to unity.
3.3. Effects of 4-DAMP on muscarinic receptors
In order to estimate the relative distribution of M2 and M3
muscarinic receptor subtypes in the urothelium and detrusor
muscle, speciﬁc [3H]NMS binding was examined by a pretreatmentf the speciﬁc binding of [3H]NMS and [3H]ab-Me-ATP in the urothelium and detrusor
:), DPr-P-4 (N/ O) (A), and propiverine (C). Lower panel, purinergic agents: ab-
0.5 nM) or [3H]ab-Me-ATP (3.0 nM) (% of control). The abscissa is the logarithmic molar
e10 mM), and propiverine (30e3000 nM) (upper panel), as well as those of ab-Me-ATP
ents the mean ± SEM of three to eight rats.
Table 2
Ki values and Hill coefﬁcients (nH) for in vitro inhibition by ab-MeATP, A317491 and
PPADS of speciﬁc [3H]ab-MeATP binding in the urothelium and detrusor muscle in
the rat bladder.
Drug Urothelium Detrusor muscle
Ki (nM) nH Ki (nM) nH
ab-MeATP 1.58 ± 0.37 0.94 ± 0.04 1.78 ± 0.30 0.96 ± 0.02
A317491 2741 ± 273 0.85 ± 0.05 2992 ± 342 0.77 ± 0.05
PPADS 3081 ± 437 0.84 ± 0.08 3642 ± 304 0.93 ± 0.11
The speciﬁc binding of [3H]ab-MeATP (3.0 nM) in rat tissues was measured in the
absence and presence of different concentrations of A317491 and PPADS. The Ki and
Hill coefﬁcients were estimated. Each value represents the mean ± SEM of four to
eight rats.
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caused signiﬁcant decreases (36%, 22% and 30%, respectively) in
Bmax values for speciﬁc [3H]NMS binding in the urothelium and
detrusor muscle compared with control values (Table 3). Bmax
values of M3 receptors in the urothelium and detrusor muscle
(37.3 ± 10.0 and 27.2 ± 4.0 fmol/mg protein, respectively) were
estimated from decreases in the Bmax values. Thus, the Bmax value
was signiﬁcantly higher in the urothelium than in the detrusor
muscle.
3.4. Effects of CYP treatment on muscarinic and P2X receptors
The Bmax values for speciﬁc [3H]NMS binding were signiﬁcantly
lower in the urothelium (39%) and detrusor muscle (19%) of CYP-
treated rats than in those of control rats (Table 4). A signiﬁcant
decrease was also observed in Bmax values for speciﬁc [3H]ab-
MeATP binding in CYP-treated rats, with decreases of 55% and 32%
in the urothelium and detrusor muscle, respectively (Table 4). On
the other hand, Kd values for the speciﬁc binding of [3H]NMS and
[3H]ab-MeATP in both tissues were not signiﬁcantly altered by the
CYP treatment.
3.5. Effects of RTX treatment on muscarinic and P2X receptors
After the intravesical instillation of RTX (10, 100 nM/0.2 mL per
rat) for 30 min, no signiﬁcant alterations were observed from
control values in the Kd or Bmax values for speciﬁc [3H]NMS binding
in the urothelium and detrusormuscle (Table 5). On the other hand,
the Bmax values for [3H]ab-MeATP binding in these tissues were
signiﬁcantly lower (30% and 26%, respectively) than control values
after the intravesical instillation of RTX (100 nM). The instillation of
a lower concentration (10 nM) of RTX did not markedly affect Bmax
values for [3H]ab-MeATP binding. The Kd values for speciﬁc [3H]ab-
MeATP binding in each tissue were not signiﬁcantly different from
control values.
3.6. Effects of intravesical instillation of imidafenacin and DPr-P-4
(N/ O) on muscarinic receptors
The Kd values for speciﬁc [3H]NMS binding in the urothelium
and/or detrusor muscle were signiﬁcantly higher than the controlTable 3
Effects of 4-DAMP mustard on Kd and Bmax for speciﬁc [3H]NMS binding in rat tissues.
Tissue Control
Kd (pM) Bmax (fmol/mg pr
Urothelium 259 ± 24 105 ± 7
Detrusor muscle 289 ± 11 125 ± 3
The speciﬁc binding of [3H]NMS (0.06e1.5 nM) in rat tissues was measured in the absence
relative to controls. Asterisks show a signiﬁcant difference from the control values, *P <values following the intravesical instillation of imidafenacin
(300 nM/0.2 mL/rat) for 30 min (Table 6). Increases of 27% (uro-
thelium) and 12% (detrusor muscle) were noted. The intravesical
instillation of a lower concentration of imidafenacin (30 nM/
0.2 mL/rat) for 30 min signiﬁcantly enhanced the Kd value for
speciﬁc [3H]NMS binding in the urothelium. On the other hand, no
signiﬁcant change was observed in the Bmax values for speciﬁc [3H]
NMS binding in these tissues following the intravesical instillation
of imidafenacin. The intravesical instillation of DPr-P-4 (N/ O) at
concentrations of 3 and 30 mM/0.2 mL/rat for 30 min led to
signiﬁcantly higher Kd values for speciﬁc [3H]NMS binding in ho-
mogenates of the urothelium than the control values without
affecting Bmax values. Increases of 16% (3 mM) and 25% (30 mM)were
noted (Table 6).4. Discussion
Muscarinic and P2X receptors were identiﬁed simultaneously
in the urothelium and the detrusor muscle of rats using the se-
lective radioligands. The estimated binding parameters revealed
similar afﬁnities and densities of these receptors in the urothelium
and detrusor muscle. Antimuscarinic agents displayed high afﬁn-
ity to speciﬁc [3H]NMS binding sites. Their afﬁnities were similar
in the urothelium and detrusor muscle, suggesting that anti-
muscarinics exhibited their therapeutic effects by blocking
muscarinic receptors in the urothelium and detrusor muscle.
Similar binding properties of antimuscarinics in the urothelium
(mucosa) and detrusor muscle have also been reported in humans
(23).
Muscarinic subtype in the urothelium is considered to activate
the afferent nerve, whereas that in the detrusor muscle is respon-
sible for muscle contraction (3). Thomas et al. (21) reported that 4-
DAMP mustard, an irreversible alkylating agent for muscarinic re-
ceptors, selectively inactivated M3 receptors over M2 receptors. The
pretreatment with 4-DAMP mustard led to signiﬁcant decreases in
the Bmax of speciﬁc [3H]NMS binding in the urothelium (36%) and
detrusor muscle (22%) of rats (Table 3), suggesting the coexistence
of M2 and M3 subtypes in these tissues. The M2 subtype is pre-
dominant in the urothelium and detrusor muscle, whereas the M3
subtype may be more prominent in the urothelium than in the
detrusor muscle.
Pharmacological concentrations of imidafenacin and Dpr-P-4
(N/ O) were shown to be excreted in the urine of patients with
OAB following the oral administration of imidafenacin and propi-
verine, respectively, at clinical dosages (9,10). The present study
revealed that the intravesical administration of imidafenacin and
Dpr-P-4 (N / O) bound muscarinic receptors in the urothelium
and detrusormuscle of rats, suggesting that these agents, which are
excreted in the urine, have direct local effects on bladder over-
activity. These results support the intravesical instillation of anti-
muscarinics reducing the distension-evoked activity of C-ﬁber
afferents in the rat bladder (24) and intravesically infused anti-
muscarinic agents suppressing the carbachol-induced bladder
overactivity (25).4-DAMP mustard treated
otein) Kd (pM) Bmax (fmol/mg protein)
243 ± 19 67.7 ± 7.6 (0.64)*
277 ± 16 97.8 ± 4.1 (0.78)**
and presence of 4-DAMPmustard (10 nM). Values in parentheses represent the Bmax
0.05, **P < 0.001. Each value represents the mean ± SEM of three to eight rats.
Table 4
Kd and Bmax for speciﬁc binding of [3H]NMS and [3H]ab-MeATP in the urothelium and detrusor muscle of control and CYP-treated rat bladders.
Ligand Tissue Control CYP-treated
Kd (pM) Bmax (fmol/mg protein) Kd (pM) Bmax (fmol/mg protein)
[3H]NMS Urothelium 259 ± 24 105 ± 7 268 ± 21 64.4 ± 4.9 (0.61)*
Detrusor muscle 289 ± 11 125 ± 3 289 ± 9 101 ± 5 (0.81)*
[3H]ab-MeATP Urothelium 1219 ± 207 9.00 ± 0.62 1214 ± 60 4.01 ± 0.85 (0.45)**
Detrusor muscle 1311 ± 97 11.1 ± 0.9 1264 ± 62 7.56 ± 1.05 (0.68)*
The speciﬁc binding of [3H]NMS (0.06e1.5 nM) and [3H]ab-MeATP (0.3e10 nM) in rat tissues was measured. Values in parentheses represent the Bmax relative to controls.
Asterisks show a signiﬁcant difference from the control values, *P < 0.05, **P < 0.01. Each value represents the mean ± SEM of four to eight rats.
Table 5
Kd and Bmax for speciﬁc binding of [3H]NMS and [3H]ab-MeATP in the urothelium and detrusor muscle of control and RTX-treated rat bladders.
Tissue Kd (pM) Bmax (fmol/mg protein)
[3H]NMS Urothelium Control 246 ± 6 126 ± 10
10 nM 269 ± 12 112 ± 8
100 nM 254 ± 6 108 ± 12
Detrusor muscle Control 272 ± 8 128 ± 6
10 nM 283 ± 11 120 ± 10
100 nM 286 ± 14 118 ± 10
[3H]ab-MeATP Urothelium Control 0.94 ± 0.06 12.0 ± 1.3
10 nM 0.99 ± 0.09 9.29 ± 0.93
100 nM 0.96 ± 0.07 8.36 ± 0.70 (0.70)*
Detrusor muscle Control 0.98 ± 0.09 14.0 ± 1.1
10 nM 0.99 ± 0.10 12.3 ± 0.5
100 nM 1.03 ± 0.05 10.4 ± 1.2 (0.74)*
The speciﬁc binding of [3H]NMS (0.1e1.5 nM) in rat tissues was measured. Each value represents the mean ± SEM of ﬁve rats. The binding of [3H]ab-MeATP (0.3e10 nM) in rat
tissues was measured. Values in parentheses represent the Bmax relative to controls. Asterisks show a signiﬁcant difference from the control values, *P < 0.05. Each value
represents the mean ± SEM of ﬁve rats.
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posed as promising therapeutic targets for OAB. Ford et al. (12)
indicated that P2X1 receptors played a signiﬁcant role in the
efferent regulation of detrusor muscle excitability and contraction,
while P2X3 and P2X2/3 receptors mediated sensory functions,
including the afferent modulation of urinary storage and elimina-
tion. The present study revealed that P2X receptors were present in
the urothelium and detrusor muscle in the rat bladder. The binding
parameters for speciﬁc [3H]ab-MeATP binding in the urothelium
were similar to those in the detrusor muscle. Furthermore, the P2X
receptor binding afﬁnities of ab-MeATP, PPADS (a nonselective
antagonist), and A-317491 (P2X3 or P2X2/3 selective antagonist) in
the urothelium were similar to those in the detrusor. Thus, these
results suggested similarities in the pharmacological characteristics
of P2X receptors in the urothelium and detrusor muscle.
The expression of bladder muscarinic and purinergic receptors
in IC models was investigated previously by immunohistochemical,
and Western and Northern blotting techniques (13,14,17).
Kageyama et al. (22) showed that a treatment with CYP down-
regulated the expression of muscarinic and P2X receptors in the
bladders of rats. This ﬁnding was further conﬁrmed by a signiﬁcantTable 6
Kd and Bmax for speciﬁc [3H]NMS binding in the urothelium and detrusor muscle in the
Drug Urothelium
Kd (pM) Bmax (f
Control 273 ± 5 107 ±
Imidafenacin 30 nM 307 ± 9 (1.12)* 113 ±
300 nM 348 ± 15 (1.27)** 120 ±
DPr-P-4 (N/ O) 3 mM 316 ± 12 (1.16)** 118 ±
30 mM 341 ± 20 (1.25)** 115 ±
Rats received 0.2 mL/body of an antimuscarinic agent intravesically, and were sacriﬁced a
rat bladder was measured. Values in parentheses represent fold-increases in Kd values
*P < 0.05, **P < 0.01. Each value represents the mean ± SEM of six rats.decrease in Bmax for [3H]NMS and [3H]ab-MeATP in the rat uro-
thelium and detrusor muscle (Table 4). Muscarinic receptors are
known to undergo compensatory regulation following signiﬁcant
changes in cholinergic neuronal activity (26). Mok et al. (27) sug-
gested a pre-junctional effect in CYP-treated bladders that
increased transmitter release in order to compensate for the down-
regulation of cholinergic and purinergic receptors. Thus, a CYP
treatment may signiﬁcantly increase neuronal activity in the
bladder, resulting in the compensatory down-regulation of phar-
macological receptors.
Birder et al. (11) also showed a marked reduction in the
expression of P2X1 in the IC bladder. Previous studies reported that
the release of ATP was signiﬁcantly increased in IC rats by a CYP
treatment (11,15). Another study clariﬁed that ATP was signiﬁcantly
elevated in the urine of individuals with IC, and the stretch-
activated release of ATP was augmented in the IC urothelium
(16). Therefore, ATP release from the urothelium may be increased
by a treatment with CYP, resulting in the compensatory down-
regulation of P2X receptors. The results of the present study indi-
cate that the densities of muscarinic and P2X receptors were
signiﬁcantly decreased not only in the detrusor muscle but also inrat bladder after the intravesical instillation of antimuscarinic agents for 30 min.
Detrusor
mol/mg protein) Kd (pM) Bmax (fmol/mg protein)
4 268 ± 6 118 ± 4
9 283 ± 12 124 ± 11
10 301 ± 12 (1.12)* 126 ± 9
9 289 ± 11 120 ± 11
11 253 ± 16 116 ± 8
t 30 min after the administration. Speciﬁc binding of [3H]NMS (0.06e1.5 nM) in the
relative to controls. Asterisks show a signiﬁcant difference from the control values,
M. Ogoda et al. / Journal of Pharmacological Sciences 131 (2016) 58e63 63the urothelium of rats by the CYP treatment. Furthermore, Tempest
et al. (17) showed that the expression of P2X2 and P2X3 receptors
was signiﬁcantly altered in the urothelium in the bladder of pa-
tients with IC.
RTX, a vanilloid compound and agonist of transient receptor
potential channel1 (TRPV1), is known for its beneﬁcial effects on IC
or detrusor overactivity (28). The ATP-induced facilitation of the
micturition reﬂex in rats was previously shown to be effectively
antagonized by a treatment with RTX (29). The intravesical instil-
lation of RTX in patients with neurogenic detrusor overactivity led
to a signiﬁcant decrease in P2X3 immunoreactivity in bladder
specimens (30). The present study revealed that the intravesical
instillation of RTX decreased the Bmax values for speciﬁc [3H]ab-
MeATP binding in the urothelium and detrusor muscle in the
bladder (Table 5). Lin et al. (31) previously reported that the
administration of RTX markedly increased endogenous ATP levels
in dorsal root ganglia and skin tissues in mice. Thus, an increase in
the release of ATP from the urothelium may cause the compensa-
tory down-regulation of purinergic receptors. Furthermore, Kuo
(32) showed that the intravesical instillation of RTX was an effec-
tive treatment for patients with detrusor overactivity refractory to
antimuscarinics. Therefore, our present results appear to be
consistent with these functional observations.
5. Conclusion
The present study revealed that 1) pharmacological character-
istics of muscarinic and P2X receptors in the urothelium of rat
bladder were similar to those in the detrusor muscle, 2) the den-
sities of these receptors were signiﬁcantly altered by pretreatments
with CYP and RTX, and 3) these receptors may be pharmacologi-
cally affected by imidafenacin and Dpr-P-4 (N/ O) excreted in the
urine. This is the ﬁrst study to characterize pharmacologically-
relevant receptors in the rat urothelium using a radioligand bind-
ing assay.
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